PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC
Clinical trial NCT04273100 · UNKNOWN
Trial details
- NCT number
- NCT04273100
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-11-14
- Primary completion
- 2020-12-31
- Enrollment
- 56
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.